Overview

  • Product name
    GDC-0941 (Pictilisib)
  • Description
    Potent PI3K inhibitor
  • Alternative names
    • Pictilisib
  • Biological description
    Potent PI3K inhibitor (IC50 values are 3, 3, 33 and 75 nM for p110α, p110δ, p110β and p110γ respectively). Induces apoptosis and shows antiproliferative effects. Shows antitumor effects in vivo.
  • Purity
    > 95%

Properties

References

This product has been referenced in:
  • Liu Z  et al. Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents. Eur J Med Chem 87:782-93 (2014). Read more (PubMed: 25440879) »
  • Wallin JJ  et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res 18:3901-11 (2012). Read more (PubMed: 22586300) »
  • O'Brien C  et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 16:3670-83 (2010). Read more (PubMed: 20453058) »
See all 2 Publications for this product

Customer reviews and Q&As

Incubated mouse brain pericytes with 5uM Pictilisib for 24hr then stimulated cells with growth factor up to 60min. Examined downstream signalling pathway Akt.

Abcam user community

Verified customer

Submitted Oct 30 2018

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up